| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
106,981,000 |
| Market
Cap: |
3.19(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$25.56 - $60.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 304 |
| Guru Rank Value : 6.1 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine is an oral selective nonpeptide somatostatin receptor type 2 agonists designed for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is Co.'s investigational, oral, nonpeptide somatostatin receptor type 5 agonist designed for the treatment of congenital hyperinsulinism. CRN04894 is Co.'s investigational, oral, nonpeptide product candidate designed to antagonize adrenocorticotrophic hormone, or ACTH, intended for the treatment of diseases caused by excess ACTH.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
97,483 |
150,268 |
313,610 |
974,317 |
| Total Sell Value |
$3,141,877 |
$5,239,932 |
$13,761,801 |
$39,297,987 |
| Total People Sold |
1 |
4 |
6 |
9 |
| Total Sell Transactions |
1 |
7 |
21 |
50 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Betz Stephen F. |
Chief Scientific Officer |
• – – |
2025-06-12 |
4 |
AS |
$32.23 |
$3,141,877 |
D/D |
(97,483) |
99,713 |
|
-7% |
|
| Betz Stephen F. |
Chief Scientific Officer |
• – – |
2025-06-12 |
4 |
OE |
$1.91 |
$291,078 |
D/D |
88,170 |
197,196 |
|
- |
|
| Vivaldi Coelho Rogerio |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
21,300 |
|
- |
|
| Nichols Weston |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
16,300 |
|
- |
|
| Fust Matthew K |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
28,836 |
|
- |
|
| Okey Stephanie |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
16,300 |
|
- |
|
| Bedrosian Camille L |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
16,300 |
|
- |
|
| Deardorf Caren |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
16,300 |
|
- |
|
| Wierenga Wendall D |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
116,146 |
|
- |
|
| Struthers Richard Scott |
President & CEO |
• • – |
2025-05-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
90,400 |
661,205 |
|
- |
|
| Struthers Richard Scott |
President & CEO |
• • – |
2025-05-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
90,400 |
320,017 |
|
- |
|
| Struthers Richard Scott |
President & CEO |
• • – |
2025-04-02 |
4 |
OE |
$1.91 |
$155,226 |
D/D |
81,270 |
410,417 |
|
- |
|
| Knight Jeff E. |
Chief Operating Officer |
• – – |
2025-03-19 |
4 |
AS |
$34.17 |
$244,964 |
D/D |
(7,162) |
87,491 |
|
-14% |
|
| Pizzuti Dana |
Chief Med and Dev Officer |
• – – |
2025-03-19 |
4 |
AS |
$34.17 |
$86,021 |
D/D |
(2,515) |
72,233 |
|
-14% |
|
| Betz Stephen F. |
Chief Scientific Officer |
• – – |
2025-03-19 |
4 |
AS |
$34.17 |
$197,353 |
D/D |
(5,770) |
108,588 |
|
-14% |
|
| Struthers Richard Scott |
President & CEO |
• • – |
2025-03-19 |
4 |
AS |
$34.17 |
$593,017 |
D/D |
(17,338) |
329,147 |
|
-14% |
|
| Schilke Tobin |
Chief Financial Officer |
• – – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
52,000 |
52,000 |
|
- |
|
| Struthers Richard Scott |
President & CEO |
• • – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
89,000 |
346,485 |
|
- |
|
| Betz Stephen F. |
Chief Scientific Officer |
• – – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
43,000 |
114,358 |
|
- |
|
| Pizzuti Dana |
Chief Med and Dev Officer |
• – – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
43,000 |
74,748 |
|
- |
|
| Knight Jeff E. |
Chief Operating Officer |
• – – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
43,000 |
94,653 |
|
- |
|
| Pizzuti Dana |
Chief Med and Dev Officer |
• – – |
2025-02-03 |
4 |
AS |
$39.07 |
$195,350 |
D/D |
(5,000) |
31,748 |
|
-17% |
|
| Pizzuti Dana |
Chief Med and Dev Officer |
• – – |
2025-02-03 |
4 |
OE |
$16.89 |
$84,450 |
D/D |
5,000 |
36,748 |
|
- |
|
| Pizzuti Dana |
Chief Med and Dev Officer |
• – – |
2025-01-07 |
4 |
OE |
$19.64 |
$49,100 |
D/D |
2,500 |
31,748 |
|
- |
|
| Pizzuti Dana |
Chief Med and Dev Officer |
• – – |
2025-01-03 |
4 |
AS |
$52.09 |
$781,350 |
D/D |
(15,000) |
29,248 |
|
-41% |
|
248 Records found
|
|
Page 1 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.36 (1.22%) 
